Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin and PCSK9 inhibitors in liver transplant patients
NCT05537948Phase 4Active, not recruiting
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pitavastatin, evolocumab and alirocumab in hyperlipidemia, sponsored by National Medical Research Center for Therapy and Preventive Medicine. Started Oct 2021; status: active, not recruiting.
02
Drugs
pitavastatinevolocumabalirocumab
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT05537948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537948.